PubRank

Naoki Hosen

Author PubWeight™ 49.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004 2.58
2 Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat Genet 2009 2.52
3 The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2002 2.25
4 Transcriptional profiling of antigen-dependent murine B cell differentiation and memory formation. J Immunol 2007 1.63
5 Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 2002 1.32
6 AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 2005 1.26
7 Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003 1.18
8 Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 2003 1.15
9 Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002 1.08
10 Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. Int J Oncol 2009 1.08
11 Solitary right ventricle metastasis by renal cell carcinoma. J Am Soc Echocardiogr 2004 1.06
12 Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci 2004 1.02
13 Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002 0.98
14 Self-renewal of the long-term reconstituting subset of hematopoietic stem cells is regulated by Ikaros. Stem Cells 2009 0.98
15 Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Cancer Sci 2003 0.96
16 Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother 2014 0.95
17 WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer 2009 0.95
18 Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 2003 0.94
19 CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro Oncol 2011 0.94
20 Expression of AA4.1 marks lymphohematopoietic progenitors in early mouse development. Proc Natl Acad Sci U S A 2009 0.93
21 WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. ScientificWorldJournal 2007 0.91
22 Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 2006 0.91
23 WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol 2004 0.90
24 Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 2007 0.89
25 High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ. Cancer Sci 2009 0.86
26 Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res 2004 0.84
27 Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies. Cancer Sci 2009 0.84
28 Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn J Clin Oncol 2010 0.84
29 WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur J Haematol 2010 0.84
30 The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model. Transpl Immunol 2003 0.83
31 WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. Anticancer Res 2012 0.83
32 WT1 peptide vaccination for the treatment of hematological malignancies: the present status and future direction. Rinsho Ketsueki 2009 0.82
33 The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells. Int J Hematol 2003 0.82
34 WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. J Cancer Res Clin Oncol 2012 0.81
35 The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver. Biochem Biophys Res Commun 2005 0.81
36 Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration. Vaccine 2011 0.81
37 "Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development. Curr Med Chem 2008 0.80
38 Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. Cancer Immunol Immunother 2015 0.80
39 Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope. Microbiol Immunol 2008 0.80
40 WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide. Anticancer Agents Med Chem 2009 0.77
41 A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. Anticancer Res 2010 0.77
42 HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells. J Immunother 2013 0.77
43 Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 2003 0.77
44 Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Mod Rheumatol 2014 0.77
45 [Multiple myeloma stem cell]. Nihon Rinsho 2015 0.76
46 Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis. Anticancer Res 2014 0.76
47 Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor. Anticancer Res 2012 0.76
48 Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors. Cancer Sci 2012 0.76
49 Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation 2002 0.76
50 Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer. Jpn J Clin Oncol 2004 0.76
51 Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients. Cancer Immunol Immunother 2015 0.76
52 Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation. Transplantation 2004 0.75
53 [Identification of myeloma-initiating cells and development of their targeting therapy]. Rinsho Ketsueki 2013 0.75
54 Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy. Oncol Res Treat 2017 0.75
55 An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells. J Immunother 2016 0.75
56 [Identification and targeting of multiple myeloma stem cells]. Nihon Rinsho 2015 0.75
57 Functional human Th17 clones with WT1-specific helper activity. Cancer Immunol Immunother 2012 0.75
58 [WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms]. Rinsho Ketsueki 2011 0.75